Dr. Talati is an Assistant Member at Moffitt Cancer Center in the Department of Malignant Hematology. She earned her MD from American University of Antigua College of Medicine (Kasturba Medical College, India), completed an Internal Medicine Residency at University at Buffalo (SUNY Buffalo), and completed a Hematology and Medical Oncology Fellowship at the University of South Florida College of Medicine and Moffitt Cancer Center.
Dr. Talati’s clinical interests include management of patients with myeloid malignancies with a focus on Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndromes (MDS). Dr. Talati’s research interests include optimizing the current prognostic systems and treatment strategies for patients with myeloid malignancies, with particular interest in designing early phase clinical trials for patients with AML.
Education & Training
USF/Moffitt Cancer Center - Hematology Oncology
University of Buffalo - Internal Medicine
American University of Antigua College of Medicine - MD
CLINICAL TRIAL 20292
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation
Condition: Malignant Hematology
Intervention: SNDX-5613 ()
CLINICAL TRIAL 20749
A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Condition: Malignant Hematology
Intervention: CA-4948 ()
Gesiotto QJ, Swoboda DM, Shallis RM, Al Ali N, Padron E, Kuykendall AT, Song J, Talati C, Sweet K, Lancet JE, Zeidan AM, Komrokji RS, Sallman DA. Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies. Clin Lymphoma Myeloma Leuk. 2021 Jun.21(6):421-424.e2. Pubmedid: 33583730.
Jain AG, Talati C, Pinilla-Ibarz J. Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia. Expert Opin Inv Drug. 2021 Jun.30(6):595-601. Pubmedid: 34053383.
Hunter AM, Al Ali N, Mai A, Shah S, Swoboda DM, Kuykendall A, Talati C, Sweet KL, Sallman DA, Lancet JE, Komrokji RS, Padron E. Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy. Leuk Res. 2021 Jun.109:106640. Pubmedid: 34144312.
Schwabkey ZI, Al Ali N, Chan O, Sallman DA, Padron E, Kuykendall AT, Talati C, Sweet K, Lancet JE, Komrokji RS. Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype. Clin Lymphoma Myeloma Leuk. 2021 Jan.21(1):e52-e56. Pubmedid: 33093008.
Swoboda DM, Ali NA, Chan O, Padron E, Kuykendall AT, Song J, Hussaini M, Talati C, Sweet K, Lancet JE, Sallman DA, Komrokji RS. PTPN11 mutations are associated with poor outcomes across myeloid malignancies. Leukemia. 2021 Jan.35(1):286-288. Pubmedid: 33132383.
Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, Hussaini M, Talati C, Sweet KL, Lancet JE, Padron E, List AF, Sallman DA. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021 Feb.5(4):1017-1028. Pubmedid: 33591325. Pmcid: PMC7903224.
Schwabkey Z, Al Ali N, Sallman D, Kuykendall A, Talati C, Sweet K, Lancet J, Padron E, Komrokji R. Impact of obesity on survival of patients with myelodysplastic syndromes. Hematology. 2021 Dec.26(1):393-397. Pubmedid: 34029507.
Mangaonkar AA, Swoboda DM, Lasho TL, Finke C, Ketterling RP, Reichard KK, Padron E, Talati C, Patnaik MM. Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. Leukemia. 2021 Apr. Pubmedid: 33931725.
Elmeliegy M, Den Haese J, Talati C, Wetzler M, Jusko WJ. Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia. Cancer Chemother Pharmacol. 2020 Sep.86(3):325-337. Pubmedid: 32748108. Pmcid: PMC7539618.
Melody M, Kuykendall A, Sallman D, Al Ali N, Zhang L, Talati C, Padron E, Sweet K, Extermann M, List A, Lancet J, Komrokji R. Defining Acute Myeloid Leukemia Ontogeny in Older Patients. Clin Lymphoma Myeloma Leuk. 2020 May.20(5):312-315. Pubmedid: 32139296.
Asghari H, Talati C. Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics. Curr Opin Hematol. 2020 Mar.27(2):66-75. Pubmedid: 31922971.
Talati C, Frantz D, Lubas A, Salamanca C, Tobon K, Kubal T. How I treat newly diagnosed acute myeloid leukemia in an outpatient setting: a multidisciplinary team perspective. Future Oncol. 2020 Mar.16(7):281-291. Pubmedid: 31985277.
Talati C, Goldberg AD, Przespolewski A, Chan O, Ali NA, Kim J, Famulare C, Sallman D, Padron E, Kuykendall A, Lancet JE, Wang E, Tallman MS, Komrokji R, Sweet K. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leuk Res. 2020 Jun.93:106367. Pubmedid: 32408060. Pmcid: PMC7771257.
Talati C, Dhulipala VC, Extermann M, Al Ali N, Kim J, Komrokji R, Sweet K, Kuykendall A, Sehovic M, Reljic T, Djulbegovic B, Lancet JE. Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia. Haematologica. 2020 Jan.105(2):398-406. Pubmedid: 31073071. Pmcid: PMC7012500.
Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, Carr RM, Binder M, Finke CM, Gangat N, Al-Kali A, Begna KH, Reichard KK, Ketterling RP, Al Ali NH, Vafaii P, Zhang L, Padron E, Talati C, Patnaik MM. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia. 2020 Feb.34(2):656-661. Pubmedid: 31511613.
Chan O, Talati C, Isenalumhe L, Shams S, Nodzon L, Fradley M, Sweet K, Pinilla-Ibarz J. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Adv. 2020 Feb.4(3):530-538. Pubmedid: 32045474. Pmcid: PMC7013263.
Castillo-Tokumori F, Talati C, Al Ali N, Sallman D, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2020 Dec.20(12):e956-e960. Pubmedid: 32778513.
Pavlovsky C, Chan O, Talati C, Pinilla-Ibarz J. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia. Future Oncol. 2019 Jan.15(3):257-269. Pubmedid: 30251548.
Andrew K, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. Am J Hematol. 2019 Jan.94(1):87-92. Pubmedid: 30390311.
Kuykendall AT, Talati C, Padron E, Sweet K, Lancet JE, List AF, Sallman D, Komrokji RS. Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis. Am J Hematol. 2019 Dec.94(12):E314-E317. Pubmedid: 31444809.
Chan O, Talati C, Sweet K, Pinilla-Ibarz J. Can increased immunogenicity in chronic myeloid leukemia improve outcomes?. Expert Rev Hematol. 2019 Apr.12(4):225-233. Pubmedid: 30855193.
Talati C, Sallman D, List AF. SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q. Clin Lymphoma Myeloma Leuk. 2018 Oct.18(10):629-635. Pubmedid: 30097406.
Talati C, Sweet K. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape. Leuk Res. 2018 Oct.73:58-66. Pubmedid: 30223250.
Talati C, Sweet KL. Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives. Int J Hematol Oncol. 2018 Oct.7(3):IJH04. Pubmedid: 30405902. Pmcid: PMC6219429.
Talati C, Lancet JE. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia. Future Oncol. 2018 May.14(12):1147-1154. Pubmedid: 29378418.
Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018 Mar.97(3):435-441. Pubmedid: 29189896.
Talati C, Pinilla-Ibarz J. Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents. Curr Opin Hematol. 2018 Mar.25(2):154-161. Pubmedid: 29266016.
Sandoval-Sus JD, Chavez JC, Dalia S, Naqvi SMH, Talati C, Nodzon L, Kharfan-Dabaja MA, Pinilla-Ibarz J. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 Jan.59(1):59-68. Pubmedid: 28641468. Pmcid: PMC7771359.
Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood. 2017 Mar.129(13):1881-1883. Pubmedid: 28159734.
Talati C, Sallman D, List A. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. Semin Hematol. 2017 Jul.54(3):159-166. Pubmedid: 28958290.
Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. Clin Lymphoma Myeloma Leuk. 2017 Dec.17(12):e45-e53. Pubmedid: 28869184.
Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol. 2017 Apr.8(2):256-265. Pubmedid: 28480065. Pmcid: PMC5401857.
Talati C, Griffiths EA, Wetzler M, Wang ES. Polo-like kinase inhibitors in hematologic malignancies. Crit Rev Oncol Hematol. 2016 Feb.98:200-210. Pubmedid: 26597019.
Talati C, Padron E. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T. Curr Hematol Malig Rep. 2016 Dec.11(6):425-433. Pubmedid: 27664113.
Wei L, Liu S, Conroy J, Wang J, Papanicolau-Sengos A, Glenn ST, Murakami M, Liu L, Hu Q, Conroy J, Miles KM, Nowak DE, Liu B, Qin M, Bshara W, Omilian AR, Head K, Bianchi M, Burgher B, Darlak C, Kane J, Merzianu M, Cheney R, Fabiano A, Salerno K, Talati C, Khushalani NI, Trump DL, Johnson CS, Morrison CD. Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib. Cold Spring Harb Mol Case Stud. 2015 Oct.1(1):a000380. Pubmedid: 27148567. Pmcid: PMC4850888.
Talati C, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M. How we will treat chronic myeloid leukemia in 2016. Blood Rev. 2015 Mar.29(2):137-142. Pubmedid: 25555325. Pmcid: PMC4385463.
Thirunavukarasu P, Talati C, Munjal S, Attwood K, Edge SB, Francescutti V. Effect of Incorporation of Pretreatment Serum Carcinoembryonic Antigen Levels Into AJCC Staging for Colon Cancer on 5-Year Survival. JAMA Surg. 2015 Aug.150(8):747-755. Pubmedid: 26083632.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub